315 related articles for article (PubMed ID: 8648367)
1. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Rothenberg ML; Eckardt JR; Kuhn JG; Burris HA; Nelson J; Hilsenbeck SG; Rodriguez GI; Thurman AM; Smith LS; Eckhardt SG; Weiss GR; Elfring GL; Rinaldi DA; Schaaf LJ; Von Hoff DD
J Clin Oncol; 1996 Apr; 14(4):1128-35. PubMed ID: 8648367
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
Pitot HC; Wender DB; O'Connell MJ; Schroeder G; Goldberg RM; Rubin J; Mailliard JA; Knost JA; Ghosh C; Kirschling RJ; Levitt R; Windschitl HE
J Clin Oncol; 1997 Aug; 15(8):2910-9. PubMed ID: 9256135
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
Comella P; Biglietto M; Casaretti R; De Lucia L; Avallone A; Maiorino L; Di Lullo L; De Cataldis G; Rivellini F; Comella G
Oncology; 2001; 60(2):127-33. PubMed ID: 11244327
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
Saliba F; Hagipantelli R; Misset JL; Bastian G; Vassal G; Bonnay M; Herait P; Cote C; Mahjoubi M; Mignard D; Cvitkovic E
J Clin Oncol; 1998 Aug; 16(8):2745-51. PubMed ID: 9704727
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Rougier P; Bugat R; Douillard JY; Culine S; Suc E; Brunet P; Becouarn Y; Ychou M; Marty M; Extra JM; Bonneterre J; Adenis A; Seitz JF; Ganem G; Namer M; Conroy T; Negrier S; Merrouche Y; Burki F; Mousseau M; Herait P; Mahjoubi M
J Clin Oncol; 1997 Jan; 15(1):251-60. PubMed ID: 8996150
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.
Conti JA; Kemeny NE; Saltz LB; Huang Y; Tong WP; Chou TC; Sun M; Pulliam S; Gonzalez C
J Clin Oncol; 1996 Mar; 14(3):709-15. PubMed ID: 8622015
[TBL] [Abstract][Full Text] [Related]
8. Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer.
Rosati G; Cordio S
Tumori; 2006; 92(4):290-4. PubMed ID: 17036518
[TBL] [Abstract][Full Text] [Related]
9. A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma.
Kalofonos HP; Skarlos D; Bafaloukos D; Papakostas P; Bamias A; Janinis J; Timotheadou E; Kouvatseas G; Stavropoulos M; Economopulos T; Fountzilas G
Cancer Invest; 2003; 21(6):855-62. PubMed ID: 14735689
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.
Delioukina ML; Prager D; Parson M; Hecht JR; Rosen P; Rosen LS
Cancer; 2002 Apr; 94(8):2174-9. PubMed ID: 12001114
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
[TBL] [Abstract][Full Text] [Related]
14. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
[TBL] [Abstract][Full Text] [Related]
15. A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer.
Reina JJ; Aparicio J; Salvador J; Pica JM; Rueda A; Lorenzo A; de la Puente CG; Borrega P; Moreno-Nogueira JA
Cancer Chemother Pharmacol; 2003 Oct; 52(4):339-45. PubMed ID: 12851783
[TBL] [Abstract][Full Text] [Related]
16. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
[TBL] [Abstract][Full Text] [Related]
17. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.
Fuchs CS; Moore MR; Harker G; Villa L; Rinaldi D; Hecht JR
J Clin Oncol; 2003 Mar; 21(5):807-14. PubMed ID: 12610178
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
Calvo E; Cortés J; Rodríguez J; Fernández-Hidalgo O; Rebollo J; Martín-Algarra S; García-Foncillas J; Martínez-Monge R; de Irala J; Brugarolas A
Clin Colorectal Cancer; 2002 Aug; 2(2):104-10. PubMed ID: 12453325
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
Goto A; Yamada Y; Hosokawa A; Ura T; Arai T; Hamaguchi T; Muro K; Shimada Y; Shirao K
Int J Clin Oncol; 2004 Oct; 9(5):364-8. PubMed ID: 15549585
[TBL] [Abstract][Full Text] [Related]
20. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
Falcone A; Di Paolo A; Masi G; Allegrini G; Danesi R; Lencioni M; Pfanner E; Comis S; Del Tacca M; Conte P
J Clin Oncol; 2001 Aug; 19(15):3456-62. PubMed ID: 11481350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
